Immunosuppression is associated with a lower risk of moderate to severe acute respiratory distress syndrome in COVID-19.
Enric Monreal(Hospital Universitario Ramón y Cajal), Jaime Masjuán(Universidad de Alcalá), Beatriz Montero‐Errasquín(Universidad de Alcalá), Juan Luis Chico‐García(Universidad de Alcalá), Álvaro Beltrán‐Corbellini(Universidad de Alcalá), Nuria García‐Barragán(Instituto Cajal), Javier Buisán(Instituto Cajal), Íñigo Corral(Hospital Universitario Ramón y Cajal), Rafael Toledano(Hospital Ruber Internacional), Javier Martínez‐Sanz(Instituto de Salud Carlos III), Lucienne Costa‐Frossard(Universidad de Alcalá), Pedro Gullón(Universidad de Alcalá), Luís Manzano(Universidad de Alcalá), Paula Pérez‐Torre(Hospital Universitario Ramón y Cajal), Araceli Alonso‐Cánovas(Universidad de Alcalá), María Consuelo Matute-Lozano(Instituto Cajal), José Luis López-Sendón(Hospital Universitario Ramón y Cajal), Guillermo García‐Ribas(Instituto Ramón y Cajal de Investigación Sanitaria), Jesús Fortün(Evidence (Italy)), Luis Máiz‐Carro(Universidad de Alcalá), Elena Natera‐Villalba(Universidad de Alcalá)
Cited by 3
Related Papers
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
|Clinical Microbiology and Infection|2018|1.5k
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|823
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials
|European Heart Journal|2017|643
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
|The Lancet HIV|2020|396